8-K: RadNet Q3 Revenue, EBITDA Soar; 2025 Guidance Raised

RadNet, Inc. reported record third-quarter revenue and Adjusted EBITDA, leading to an upward revision of its full-year 2025 financial guidance.

Summary

• Total Company Revenue increased 13.4% to $522.9 million in the third quarter of 2025 from $461.1 million in the third quarter of 2024.
• Digital Health reportable segment revenue (inclusive of intersegment revenue) increased 51.6% to $24.8 million in the third quarter of 2025 from $16.4 million in the third quarter of 2024.
• Total Company Adjusted EBITDA was $84.9 million in the third quarter of 2025, an increase of 15.2% from $73.7 million in the third quarter of 2024.
• Adjusted Diluted Earnings Per Share was $0.20 for the third quarter of 2025, compared with $0.18 for the third quarter of 2024.
• Aggregate advanced imaging (MRI, CT, and PET/CT) procedural volumes increased 13.0%, and same-center advanced imaging procedural volumes increased 9.9% as compared with the third quarter of 2024.
• RadNet revises full-year 2025 guidance levels upwards for Imaging Center Revenue and Adjusted EBITDA ranges, and Digital Health Revenue ranges.
• As of September 30, 2025, the company had a cash balance of $804.7 million and a Net Debt to Adjusted EBITDA ratio of approximately 1.0x.

Sentiment

Score: 8

Explanation: The filing reports record quarterly revenue and Adjusted EBITDA, significant growth in both core imaging and digital health segments, and an upward revision of full-year guidance. The strong balance sheet and liquidity position further enhance the positive outlook, despite some one-time expenses impacting net income.

Positives

• Achieved record quarterly revenue of $522.9 million, a 13.4% increase over Q3 2024.
• Reported record quarterly Adjusted EBITDA of $84.9 million, a 15.2% increase over Q3 2024.
• Digital Health segment revenue grew significantly by 51.6% to $24.8 million in Q3 2025.
• Adjusted EBITDA margins expanded by 26 basis points to 16.2% in Q3 2025.
• Adjusted Diluted Earnings Per Share increased to $0.20 in Q3 2025 from $0.18 in Q3 2024.
• Strong aggregate advanced imaging procedural volume growth of 13.0% and same-center growth of 9.9%.
• Advanced imaging business mix increased by 153 basis points to 28.2% of all procedures.
• Full-year 2025 guidance for Imaging Center Revenue was raised to $1,900 $1,930 million (from $1,850 $1,900 million).
• Full-year 2025 guidance for Imaging Center Adjusted EBITDA was raised to $276 $284 million (from $271 $279 million).
• Full-year 2025 guidance for Digital Health Revenue was raised to $85 $95 million (from $80 $90 million).
• Maintained a strong balance sheet with a cash balance of $804.7 million and a low Net Debt to Adjusted EBITDA ratio of approximately 1.0x.
• Growth attributed to creating capacity at existing centers, new center openings, business mix shift towards advanced imaging, tuck-in acquisitions, increased reimbursement, and expansion of health system joint ventures.
• MRI volume increased 14.8%, CT volume increased 9.4%, and PET/CT volume increased 21.1% in Q3 2025 compared to Q3 2024.

Negatives

• Total Company Net Income for Q3 2025 was $5.4 million, lower than Adjusted Earnings of $15.8 million due to several one-time items.
• Nine-month 2025 Total Company Net Loss was $18.1 million, compared with a $2.6 million loss for the first nine months of 2024.
• Fully diluted Net Loss Per Share for the nine-month period of 2025 was $(0.24), compared with $(0.04) in the prior year period.
• One-time items impacting Q3 2025 included: $2.6 million non-cash loss from interest rate swaps, $1.4 million severance expense, $621,000 expense for de novo facilities under construction, $5.5 million non-capitalized R&D for DeepHealth Cloud OS and AI solutions, $2.1 million acquisition transaction costs, and $2.8 million lease abandonment charges.
• Digital Health Adjusted EBITDA growth was modest at 6.9% ($3.5 million) despite a 51.6% revenue increase in Q3 2025.
• Digital Health Free Cash Flow after Non-Capitalized R&D is projected to be negative for 2025, with a revised guidance range of $(6) $(9) million.

Risks

• The availability and terms of capital to fund the business.
• Ability to service indebtedness, make principal and interest payments, comply with debt covenants, and refinance indebtedness on acceptable terms.
• Changes in general economic conditions nationally and regionally in the markets of operation.
• Ability to acquire, develop, implement, and monetize technology, digital health initiatives, and artificial intelligence algorithms and applications.
• Volatility in interest and exchange rates, or credit markets.
• Adequacy of cash flow and earnings to fund current and future operations.
• Changes in service mix, revenue mix, and procedure volumes.
• Delays in receiving payments for services provided.
• Increased bankruptcies among partner physicians or joint venture partners.
• Impact of the political environment and related developments on the current healthcare marketplace and business, including with respect to the future of the Affordable Care Act.
• Reduction in coverage or reimbursement rates for services, or other material impacts to the business, due to healthcare reform, new legislation, regulations, enforcement, or litigation.
• Closures or slowdowns and changes in labor costs and labor difficulties, including stoppages.
• The occurrence of hostilities, political instability, or catastrophic events.
• The emergence or reemergence of and effects related to future pandemics, epidemics, and infectious diseases.
• Noncompliance with any privacy or security laws or any cybersecurity incident or other security breach involving the misappropriation, loss, or unauthorized use or disclosure of confidential information.

Future Outlook

RadNet has revised its full-year 2025 guidance upwards for Imaging Center Revenue to a range of $1,900 $1,930 million and Adjusted EBITDA to $276 $284 million. Digital Health Revenue guidance has also been raised to $85 $95 million, partly due to the contribution of iCAD revenue beginning in mid-July. The company anticipates continued strong growth and financial performance, leveraging its strong liquidity position to drive organic growth and pursue attractive strategic acquisitions in both imaging centers and digital health targets.

Management Comments

• "The business continues to demonstrate strong growth and record results in each of the Imaging Center and Digital Health reportable operating segments."
• "Total Company Revenue grew 13.4% and Adjusted EBITDA grew 15.2% as compared with last year's third quarter, resulting in Adjusted EBITDA margin expansion of 26 basis points."
• "Contributing to the achievement of these results were the continued focus on creating capacity at existing centers, new center openings, ongoing business mix shift towards advanced imaging, tuck-in acquisitions, increased reimbursement from commercial and capitated payors, the expansion of health system joint ventures and an acceleration of Digital Health Revenue growth."
• "Given the positive trends we are experiencing in virtually all aspects of the business and the strong financial performance of the third quarter, we are revising upwards certain guidance levels in anticipation of financial results that we believe will exceed both original expectations and the adjustments we made to the guidance ranges upon releasing first and second quarter 2025 results."
• "This liquidity position provides the financial flexibility to continue to drive organic growth and to pursue attractive strategic acquisitions of both imaging centers and digital health targets."
• "With respect to the Digital Health reportable segment, we updated the Revenue guidance range upwards, due in part to the contribution of iCAD Revenue beginning in mid-July."

Industry Context

RadNet's strong performance, particularly in advanced imaging and digital health, aligns with broader healthcare trends emphasizing outpatient care, technological advancements (AI in diagnostics), and efficiency. The growth in advanced imaging volumes (MRI, CT, PET/CT) reflects increasing demand for sophisticated diagnostic tools. The expansion of digital health solutions positions RadNet to capitalize on the growing integration of technology in healthcare delivery, potentially enhancing efficiency and patient outcomes across the industry. The company's strategy of creating capacity, new center openings, and strategic acquisitions indicates a proactive approach to market expansion and consolidation within the diagnostic imaging sector.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, record revenue and EBITDA, increased guidance, and potential for continued growth and strategic acquisitions.
• Employees: Potential for growth and expansion, but also severance expenses related to cost-savings initiatives were noted.
• Customers (Patients): Continued expansion of imaging centers and digital health solutions could lead to improved access and advanced diagnostic services.
• Payors: Increased reimbursement from commercial and capitated payors is a positive for the company.
• Creditors: Strong cash balance and low leverage ratio (1.0x Net Debt to Adjusted EBITDA) indicate good financial health and ability to service debt.

Next Steps

• Host a conference call to discuss Q3 2025 results on Monday, November 10, 2025, at 10:30 a.m. Eastern Time.
• Continue to drive organic growth.
• Pursue attractive strategic acquisitions of both imaging centers and digital health targets.

Key Dates

Recommendation

RadNet's Q3 2025 results demonstrate exceptional financial and operational strength, with record revenue and Adjusted EBITDA, significant growth across both core imaging and digital health segments, and robust procedural volume increases. The upward revision of full-year guidance signals management's confidence in continued strong performance. A healthy balance sheet with substantial cash and low leverage provides ample flexibility for future organic growth and strategic acquisitions. Despite some one-time expenses impacting reported net income, the underlying adjusted metrics and forward-looking statements paint a very positive picture, making it a compelling investment opportunity.

Keywords

RadNet, RDNT, diagnostic imaging, digital health, outpatient services, medical imaging, AI, DeepHealth, financial results, Q3 2025, earnings, EBITDA, revenue, guidance, healthcare, acquisitions, joint ventures, advanced imaging, MRI, CT, PET/CT